Nutex Health (NUTX) Current Deferred Revenue (2013 - 2022)

Nutex Health has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $92111.0 for Q1 2022.

• Current Deferred Revenue for Q1 2022 came in at $92111.0, up 71.09% year-over-year; the trailing twelve-month figure through Mar 2022 was $92111.0 (up 71.09% YoY), and the FY2021 annual result was $173919.0, up 126.79% from the prior year.
• Current Deferred Revenue came in at $92111.0 for Q1 2022 at Nutex Health, down from $173919.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $173919.0 in Q4 2021 to a low of $600.0 in Q3 2019.
• The 5-year median for Current Deferred Revenue is $40217.0 (2020), against an average of $52588.6.
• Across the five-year window, Current Deferred Revenue plunged 85.6% in 2019 and jumped 2743.67% in 2020, its largest moves.
• Nutex Health's Current Deferred Revenue stood at $4167.0 in 2018, then surged by 3873.12% to $165560.0 in 2019, then tumbled by 53.68% to $76687.0 in 2020, then jumped by 126.79% to $173919.0 in 2021, then sank by 47.04% to $92111.0 in 2022.
• The last three Current Deferred Revenue figures came in at $92111.0 (Q1 2022), $173919.0 (Q4 2021), and $45022.0 (Q3 2021), per Business Quant data.